Last update Oct. 12, 2022
Very High Risk
Central psychostimulant drug that is used as an anorectic in the treatment of obesity. It has similar actions than Dexamphetamine. Oral administration in a daily dose.
At latest update no published data were found on excretion into breast milk.
Pharmacokinetic data (low molecular weight and low protein binding) make it likely the passage into milk in an amount that may be significant.
Its T1/2 of 20 hours would make it necessary to stop breastfeeding for about 140 hours after its administration.
It could cause insomnia, irritability and anorexia in the infant.
Given the increased risk for cardiac valvular disorders and psychotic reactions, the European Medicines Agency (EMA) ordered the withdrawal from marketing in the European Union on 2000. (AEMPS 2000)
There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss.(Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM